Lilly and Novo Nordisk Shares Rise on FDA GLP-1 Compounding Proposal

Pharmaceutical companies Lilly and Novo Nordisk saw their stock prices increase following a proposal from the FDA to exclude GLP-1 receptor agonists from the compounding list.